Tepmetko (tepotinib)

pCPA File Number: 21997
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the treatment of adult patients with locally advanced unresectable metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations
Sponsor/Manufacturer:
EMD Serono Canada, a division of EMD Inc.
CADTH Project Number:
PC0255
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable